


Patient Safety ALERT – Novel Oral Anticoagulants

Apixaban (Eliquis®)



Dabigatran etexilate (Pradaxa®)



Rivaroxaban (Xarelto®)



Apixaban, dabigatran and rivaroxaban are novel oral anticoagulants ('NOACs') which may be prescribed for certain indications, including:

Non-valvular atrial fibrillation (NVAf)

Venous Thromboembolism (VTE) treatment or prophylaxis

Patients should not be prescribed other anticoagulant medication (such as warfarin, dalteparin, enoxaparin, tinzaparin or heparin) if apixaban, dabigatran or rivaroxaban have been prescribed, due to an increased risk of bleeding.

There is no specific reversal agent for these novel, (non-vitamin K antagonist) anticoagulants.

Regular INR (international normalised ratio) monitoring is not required.

FOR ACTION:

Ensure that ALL STAFF are aware of this when prescribing, administering or reviewing patients' medication.